Incyte: Maintaining Buy Rating As Hem/Oncology Portfolio Adds 2 Recent Wins

Group 1 - The article discusses Incyte (INCY) and highlights two untapped opportunities in its oncology portfolio, maintaining a "Buy" recommendation for the stock [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and runs the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] Group 2 - The article does not provide any specific financial data or performance metrics related to Incyte or the biotech industry [1][3][4]